루테튬 177(Lu-177) 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2024-2032년)

Growth Factors of Lutetium-177 (Lu-177) Market

The global Lutetium-177 (Lu-177) market is experiencing rapid expansion as targeted radionuclide therapy gains global prominence in cancer treatment. According to the latest assessment, the market was valued at USD 2.15 billion in 2024, is projected to rise to USD 2.73 billion in 2025, and is expected to reach USD 10.84 billion by 2032, registering a strong CAGR of 21.8% during 2025-2032. This accelerated growth is driven by increasing cancer prevalence, expanding adoption of targeted therapies, and the growing availability of next-generation Lu-177 radiopharmaceuticals.

Market Overview

Lutetium-177 is a beta-emitting radioisotope used in targeted radionuclide therapy, particularly for neuroendocrine tumors (NETs) and prostate cancer, two cancer types with rising global incidence. Its unique ability to bind to tumor receptors-such as somatostatin receptors in NETs and PSMA in prostate cancer-allows precise delivery of radiation directly to cancer cells while preserving healthy tissues. Key market players include Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals, and Radiopharm Theranostics, all actively expanding their Lu-177 portfolios and production capabilities.

The market is also supported by the global shift toward precision oncology, where radioligand therapy (RLT) is emerging as a vital treatment option for patients who fail conventional therapies.

Market Size & Key Regional Insights

North America dominated the global market in 2024, holding a substantial 82.79% share, driven by high cancer prevalence, strong reimbursement frameworks, and the presence of advanced radiopharmaceutical manufacturing facilities. Regional revenue reached USD 1.78 billion in 2024, with the U.S. leading production due to major facilities like SHINE Technologies' Lu-177 plant in Janesville, the largest in North America.

Europe accounted for the second-largest market share in 2024, supported by robust clinical infrastructure and rising adoption of targeted therapies. The launch of the Nuclear Medicine Therapy Centre in Sutton, U.K., further strengthened the region's capabilities in administering Lu-177 PSMA therapy.

Asia Pacific is projected to be the fastest-growing region, driven by rising cancer cases, expanding clinical trials, and supportive collaboration initiatives. Partnerships such as Radiopharm Theranostics' agreement with ANSTO to supply non-carrier-added Lu-177 highlight ongoing investments in advanced radiopharmaceuticals.

Market Drivers

1. Rising Cancer Prevalence

The increasing incidence of prostate cancer, neuroendocrine tumors, and other malignancies is a primary growth driver. In the U.S. alone, 313,780 new prostate cancer cases are estimated for 2025. Lu-177's ability to deliver targeted beta radiation makes it a preferred therapy for advanced and treatment-resistant cancers.

2. Growing Demand for Targeted Treatment

Targeted radionuclide therapy reduces side effects and improves treatment outcomes. Increasing adoption of products like LUTATHERA (Lu-177 dotatate) and PLUVICTO (Lu-177 vipivotide tetraxetan) continues to fuel market expansion.

Market Restraints

High treatment costs restrict adoption in lower-middle-income countries. A single dose of Pluvicto can cost USD 5,000-12,000 depending on the region, with an average treatment regimen requiring six doses. Limited radiotherapy infrastructure and insufficient reimbursement policies further challenge global adoption.

Market Opportunities

Growing clinical research presents significant opportunities. Increasing numbers of clinical trials on Lu-177 for medulloblastoma, breast cancer, glioblastoma, and NSCLC are widening the therapeutic scope. Regulatory approvals-such as the RPDD for 177Lu-omburtamab-DTPA-are expanding treatment options into pediatric oncology.

Market Trends

Combination Therapy Integration

Combining Lu-177 with immunotherapy, DNA-repair inhibitors, and chemotherapy is emerging as a key trend. Telix Pharmaceuticals' STARSTRUCK Phase I trial combining TLX250 with peposertib exemplifies this shift toward synergistic treatment options.

Segmentation Insights

By Drug

• LUTATHERA dominated in 2024 due to rising neuroendocrine tumor incidence.
• PLUVICTO is expanding rapidly, driven by high demand for prostate cancer therapeutics and improving reimbursement access in Canada and Europe.

By Age Group

• Adults held the largest share in 2024 due to high prostate cancer prevalence among men aged 65+.
• Pediatrics is expected to grow rapidly following FDA approvals for Lu-177 therapies in children aged 12+.

By Application

• Prostate cancer led the market in 2024 due to increased approvals and treatment availability.
• Neuroendocrine tumors expected strong growth driven by expanding clinical development.

By End-User

• Hospitals dominated the market in 2024 due to specialized nuclear medicine infrastructure.

Conclusion

With its market value rising from USD 2.15 billion in 2024 to USD 10.84 billion by 2032, the Lutetium-177 market is poised for transformational growth. Increasing cancer incidence, expanding radioligand therapy approvals, and strong regional production capabilities position Lu-177 as a cornerstone in the future of precision oncology.

Segmentation By Drug

• LUTATHERA (lutetium Lu 177 dotatate)
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
• Others

By Age Group

• Adults
• Pediatrics

By Application

• Neuroendocrine Tumor
• Prostate Cancer
• Others

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America (By Drug, Age Group, Application, End-User, and Country)
  • U.S.
  • Canada
• Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Rest of the World ( By Drug, Age Group, Application, and End-User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. New Product Launches, by Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
  • 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Age Group
  • 5.2.1. Adults
  • 5.2.2. Pediatrics
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Neuroendocrine Tumors
  • 5.3.2. Prostate Cancer
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By End-User
  • 5.4.1. Hospitals
  • 5.4.2. Specialty Clinics
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
  • 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Age Group
  • 6.2.1. Adults
  • 6.2.2. Pediatrics
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Neuroendocrine Tumors
  • 6.3.2. Prostate Cancer
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By End-User
  • 6.4.1. Hospitals
  • 6.4.2. Specialty Clinics
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
  • 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Age Group
  • 7.2.1. Adults
  • 7.2.2. Pediatrics
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Neuroendocrine Tumors
  • 7.3.2. Prostate Cancer
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By End-User
  • 7.4.1. Hospitals
  • 7.4.2. Specialty Clinics
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
  • 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Age Group
  • 8.2.1. Adults
  • 8.2.2. Pediatrics
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Neuroendocrine Tumors
  • 8.3.2. Prostate Cancer
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By End-User
  • 8.4.1. Hospitals
  • 8.4.2. Specialty Clinics
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
  • 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Age Group
  • 9.2.1. Adults
  • 9.2.2. Pediatrics
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Neuroendocrine Tumors
  • 9.3.2. Prostate Cancer
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By End-User
  • 9.4.1. Hospitals
  • 9.4.2. Specialty Clinics
  • 9.4.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles
  • 10.2.1. Novartis AG
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Telix Pharmaceuticals Limited
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Ariceum Therapeutics
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Radiopharm Theranostics Limited
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Lantheus Holdings, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Y-mAbs Therapeutics, Inc.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. GLYTHERIX
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Curium
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)